{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Upper+Extremity&page=10",
    "query": {
      "condition": "Upper Extremity",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 4189,
    "total_pages": 419,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Upper+Extremity&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Upper+Extremity&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T07:59:02.565Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04428151",
      "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2020-08-06",
      "completion_date": "2025-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 55,
      "location_summary": "Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428151"
    },
    {
      "nct_id": "NCT01793753",
      "title": "Effect of Propofol on Internal Anal Sphincter Pressure During ARM",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Constipation"
      ],
      "interventions": [
        {
          "name": "Propofol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "2 Years to 6 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-14",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01793753"
    },
    {
      "nct_id": "NCT03440112",
      "title": "Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Clarithromycin (Not used as of 4/2020)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Not used as of 4/2020)",
          "type": "DRUG"
        },
        {
          "name": "Transdermal flumazenil (Added 4/2020)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Added 4/2020)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicolaas Bohnen, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2018-01-29",
      "completion_date": "2021-12-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03440112"
    },
    {
      "nct_id": "NCT07874828",
      "title": "PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma,Soft Tissue"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-14",
      "completion_date": "2036-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07874828"
    },
    {
      "nct_id": "NCT07006792",
      "title": "A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2025-06-16",
      "completion_date": "2026-09-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07006792"
    },
    {
      "nct_id": "NCT03775421",
      "title": "An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Heart Disease With Fontan Circulation"
      ],
      "interventions": [
        {
          "name": "macitentan 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2019-04-11",
      "completion_date": "2022-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Spokane, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03775421"
    },
    {
      "nct_id": "NCT02072421",
      "title": "The MASS COMM Post-Randomization Phase Cohort Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "PCI",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Baim Institute for Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2879,
      "start_date": "2011-10",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 10,
      "location_summary": "Brockton, Massachusetts • Framingham, Massachusetts • Lawrence, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Brockton",
          "state": "Massachusetts"
        },
        {
          "city": "Brockton",
          "state": "Massachusetts"
        },
        {
          "city": "Framingham",
          "state": "Massachusetts"
        },
        {
          "city": "Lawrence",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072421"
    },
    {
      "nct_id": "NCT01844804",
      "title": "A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06438179",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remicade",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 146,
      "start_date": "2013-05",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-07",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844804"
    },
    {
      "nct_id": "NCT00141284",
      "title": "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "nelfinavir 1,250 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine 300 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine 150 mg twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141284"
    },
    {
      "nct_id": "NCT02350647",
      "title": "Suture Anchor Comparison in Rotator Cuff Repairs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rotator Cuff Injury"
      ],
      "interventions": [
        {
          "name": "Suture Anchor HEALOCOIL",
          "type": "DEVICE"
        },
        {
          "name": "Suture anchor Twinfix Ultra HA",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The Hawkins Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-05",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-10-27T07:59:02.565Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02350647"
    }
  ]
}